Cannabis at the Crossroads: A Transdisciplinary Analysis and Policy Prescription

L. Trautman, Paul Seaborn, A. Sulkowski, D. Mayer, Robert T. Luttrell
{"title":"Cannabis at the Crossroads: A Transdisciplinary Analysis and Policy Prescription","authors":"L. Trautman, Paul Seaborn, A. Sulkowski, D. Mayer, Robert T. Luttrell","doi":"10.2139/ssrn.3541229","DOIUrl":null,"url":null,"abstract":"Cannabis has returned to the mainstream in recent years after an interlude of legal prohibition and partial societal stigmatization. 2019 U.S. state-legal cannabis sales have been estimated at 13.6 billion dollars with predictions for sales to near 30 billion by 2025. The global market for cannabis products - including a range of products produced from non-psychoactive hemp - could approach hundreds of billions of dollars annually. At the same time, the legal cannabis industry faces significant challenges in the United States; legalization has been uneven, with disparities among states, and federal law continues to impose obstacles to predictability in the nationwide market for cannabis. \n \nConflicts between U.S. federal and state laws regarding cannabis are numerous. Federal law treats most forms of cannabis as illegal, yet 97.7 percent of the U.S. population –– located in 47 states, the District of Columbia, and 4 U.S. territories –– are living in jurisdictions where medical or recreational use of cannabis, including cannabidiol (“CBD”) oil, is now legal. \n \nThis Article takes a transdisciplinary approach and proceeds in eight parts. First, we explore the history of cannabis including its earliest uses, noting periodic prohibitions. Second, we look at applicable current U.S. federal statutes, both criminal and non-criminal. Third, we consider the legalization approaches and experiences in the states. Fourth, we look at the Canadian experience including national recreational market legalization in 2018. Fifth, we examine the ethical issues around recreational and medical marijuana use. Sixth, we describe the future outlook for cannabis businesses in terms of both market potential and regulation. Seventh, we describe Congressional proposals to change federal laws on cannabis. Eighth, we then draw upon these various perspectives to arrive at a policy prescription. And last, we conclude.","PeriodicalId":150377,"journal":{"name":"Medical Ethics eJournal","volume":"51 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Ethics eJournal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3541229","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Cannabis has returned to the mainstream in recent years after an interlude of legal prohibition and partial societal stigmatization. 2019 U.S. state-legal cannabis sales have been estimated at 13.6 billion dollars with predictions for sales to near 30 billion by 2025. The global market for cannabis products - including a range of products produced from non-psychoactive hemp - could approach hundreds of billions of dollars annually. At the same time, the legal cannabis industry faces significant challenges in the United States; legalization has been uneven, with disparities among states, and federal law continues to impose obstacles to predictability in the nationwide market for cannabis. Conflicts between U.S. federal and state laws regarding cannabis are numerous. Federal law treats most forms of cannabis as illegal, yet 97.7 percent of the U.S. population –– located in 47 states, the District of Columbia, and 4 U.S. territories –– are living in jurisdictions where medical or recreational use of cannabis, including cannabidiol (“CBD”) oil, is now legal. This Article takes a transdisciplinary approach and proceeds in eight parts. First, we explore the history of cannabis including its earliest uses, noting periodic prohibitions. Second, we look at applicable current U.S. federal statutes, both criminal and non-criminal. Third, we consider the legalization approaches and experiences in the states. Fourth, we look at the Canadian experience including national recreational market legalization in 2018. Fifth, we examine the ethical issues around recreational and medical marijuana use. Sixth, we describe the future outlook for cannabis businesses in terms of both market potential and regulation. Seventh, we describe Congressional proposals to change federal laws on cannabis. Eighth, we then draw upon these various perspectives to arrive at a policy prescription. And last, we conclude.
大麻在十字路口:一个跨学科的分析和政策处方
经过一段法律禁止和部分社会污名化的插曲,大麻近年来已回到主流。2019年美国州合法大麻销售额估计为136亿美元,预计到2025年销售额将接近300亿美元。大麻产品的全球市场——包括一系列由非精神活性大麻生产的产品——每年可能接近数千亿美元。与此同时,合法大麻产业在美国面临着重大挑战;大麻的合法化并不均衡,各州之间存在差异,联邦法律继续对全国大麻市场的可预测性设置障碍。美国联邦和州关于大麻的法律之间的冲突很多。联邦法律将大多数形式的大麻视为非法,然而97.7%的美国人口-位于47个州,哥伦比亚特区和4个美国领土-居住在医疗或娱乐使用大麻的司法管辖区,包括大麻二酚(CBD)油,现在是合法的。本文采用跨学科的研究方法,分为八个部分。首先,我们探索大麻的历史,包括其最早的使用,注意到定期禁止。其次,我们看看适用的现行美国联邦法规,刑事和非刑事。第三,我们考察了各州的合法化途径和经验。第四,我们看看加拿大的经验,包括2018年全国娱乐市场合法化。第五,我们研究了娱乐性和医用大麻使用的伦理问题。第六,我们从市场潜力和监管两方面描述了大麻业务的未来前景。第七,我们描述了国会关于改变联邦大麻法律的提案。第八,然后我们利用这些不同的观点来得出一个政策处方。最后,我们总结一下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信